Agios Advances Cancer Metabolism Collaboration with Celgene

Agios Advances Cancer Metabolism Collaboration with Celgene

December 11, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 11, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced an extension of one additional year to the period of exclusivity for their strategic cancer metabolism collaboration with Celgene Corporation (NASDAQ: CELG).

Selecta Biosciences Announces Allowance of the First in a Series of Patents on the Induction of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies

Selecta Biosciences Announces Allowance of the First in a Series of Patents on the Induction of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies

December 9, 2013

Watertown, Mass. — December 9, 2013 – Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that the US Patent and Trademark Office (USPTO) has allowed the issuance of a Selecta owned patent with the title “Tolerogenic Synthetic Nanocarriers For Inducing Regulatory B Cells”, the first in a series of patent filings on antigen-specific tolerogenic immunotherapies.

Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy

Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy

December 9, 2013

Presentation of Data at the ASH 2013 Annual Meeting

Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform

Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform

December 10, 2013

SAN DIEGO (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) announced today that Ono has elected to amend and expand the existing collaboration agreement between the parties to include transfer to Ono of the Receptos G-protein-coupled receptor (GPCR) technology platform, a proprietary high resolution protein crystal structure determination technology which enables rational drug design for the GPCR therapeutic target class.

Saudi Aramco Energy Ventures LLC Announces an Equity Investment into Novomer Inc.

Saudi Aramco Energy Ventures LLC Announces an Equity Investment into Novomer Inc.

December 10, 2013

Dhahran, Saudi Arabia and Waltham, Massachusetts – Saudi Aramco Energy Ventures LLC (“SAEV”), the corporate venturing subsidiary of Saudi Aramco, has led an investment into Novomer Inc., an emerging sustainable chemistry company pioneering a family of high performance, environmentally responsible polymers and chemical intermediates. All existing Novomer investors also participated in the financing.

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

December 10, 2013

WALTHAM, Mass., Dec. 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT® Code 82777) at the amount of a crosswalked test (analyte-specific CPT® Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.

Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting

Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting

December 9, 2013

Preclinical In Vivo Efficacy Demonstrated for IDH Inhibitors in Patient-Derived Leukemia Models

CAMBRIDGE, Mass. & NEW ORLEANS--(BUSINESS WIRE)-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that data from its lead programs were highlighted at the American Society of Hematology (ASH) Annual Meeting this week in New Orleans.

Acceleron and Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at 2013 American Society of Hematology Annual Meeting

Acceleron and Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at 2013 American Society of Hematology Annual Meeting

December 9, 2013

Dose-dependent increases in hemoglobin demonstrated in non-transfusion dependent patients Increases in hemoglobin of at least 1-2 g/dL observed in most patients at 0.3 and 0.5 mg/kg dose levels Significant relationship between hemoglobin increase and drug exposure across dose ranges tested

Sotatercept granted orphan status by the FDA for the treatment of beta-thalassemia

Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

December 5, 2013

— Data from Interim Analysis of Phase 2 Trial Provide Support to Advance Program —

— Interim Data Consistent with RPC1063 Differentiation Profile —

Software Industry Veteran Lou Shipley Named CEO of Black Duck Software

Software Industry Veteran Lou Shipley Named CEO of Black Duck Software

December 4, 2013

Extensive Experience in Cloud, Enterprise Software, Virtualization and CEO Roles Positions Black Duck for Accelerated Growth